Management of cancer anorexia/cachexia.
Cancer anorexia/cachexia is a common clinical problem that substantially impacts upon the quality of life and survival of affected patients. Extensive investigations have not supported the use of either enteral or paternal hyperalimentation for such patients. Despite positive pilot trial reports, large randomized studies have been unable to demonstrate a clinically defensible role for either pentoxifylline, cyproheptadine, or hydrazine sulfate for patients with anorexia. Multiple placebo-controlled, randomized, double-blind, clinical trials have demonstrated that corticosteroids do have appetite-enhancing properties in patients suffering from cancer anorexia/cachexia, but none of these studies has demonstrated weight gain. In comparison, multiple studies have demonstrated that the progestational agent, megestrol acetate, has both appetite-enhancing and weight-promoting properties.
Loprinzi
C L
CL
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.
D000855:Anorexia / Q000188:drug therapy* / Q000209:etiology; D002100:Cachexia / Q000188:drug therapy* / Q000209:etiology; D018849:Controlled Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D008535:Megestrol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019290:Megestrol Acetate; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000150:complications; D016032:Randomized Controlled Trials as Topic
D008535:Megestrol; D019290:Megestrol Acetate